Related Experiment Video
Updated: Aug 24, 2026

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
Published on: September 26, 2018
Managing the cost of cardiovascular prevention in primary care
1Wandsworth Primary Care Trust Headquarters, 2nd Floor, Teak Tower, Main Building, Springfield University Hospital, 61 Glenburnie Road, London SW17 7DJ, UK. norman.evans@swlondon.nhs.uk
Insights
Rising cardiovascular disease prevention costs highlight system waste. Reducing this waste can fund new treatments and improve patient care through evidence-based medicine.
Area of Science:
- Pharmacoeconomics
- Public Health Policy
- Cardiovascular Medicine
Background:
- National prescribing costs for cardiovascular disease prevention are increasing.
- Implementation of the National Service Framework for coronary heart disease is a contributing factor.
- Evidence-based medicine is crucial for effective patient management and drug funding.
Purpose of the Study:
- To analyze prescribing costs in cardiovascular disease prevention.
- To identify areas of waste within the current prescribing system.
- To explore the potential for reallocating savings to new therapeutic developments.
Main Methods:
- Analysis of national prescribing data.
- Review of current healthcare policies related to cardiovascular disease.
- Assessment of cost-effectiveness in cardiovascular drug prescribing.
Main Results:
- Significant waste identified within the current prescribing system.
- Potential for substantial cost savings through optimized prescribing practices.
- Cardiovascular disease prevention is a major area of rising expenditure.
Conclusions:
- Reducing waste in prescribing can free up resources for new drug development.
- Optimizing prescribing for cardiovascular disease prevention is essential.
- Savings achieved can benefit multiple therapeutic areas beyond cardiovascular disease.
Abstract:
Prescribing costs for the prevention of cardiovascular disease are rising nationally, particularly in relation to implementation of the National Service Framework for coronary heart disease. Prescribing effective treatment that is going to benefit the patient's overall management--evidence based medicine--is the key to funding drugs for cardiovascular prevention. It is clear that there is a lot of waste within the system. If the current waste in prescribing can be reduced, it should be possible to fund new developments, not only in cardiovascular disease but also in other therapeutic areas.
More Related Videos
06:16Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
Published on: August 9, 2024
13:07Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression
Published on: January 15, 2022
Related Concept Videos
Coronary Artery Disease IV: Preventive Measures
Preventive Healthcare Services
Atherosclerosis III: Management
Rheumatic Heart Disease III: Medical Management
Coronary Artery Disease V: Interprofessional Care
Cardiomyopathy V: Interprofessional Care